Adia Nutrition Moves to Secure Brand Identity with Trademark Filings
ADIA Nutrition Inc. (OTC Pink: ADIA) has filed trademark applications with the USPTO for its new product 'Adia Vita' and slogan 'The Platinum Standard in Stem Cell Therapy.' The company's new private-label umbilical cord stem cell product, Adia Vita, features third-party-verified content of 100 million stem cells and 3 trillion exosomes per unit.
The product is now available for purchase through Adia Labs to doctors and clinics for trials and research. According to CEO Larry Powalisz, these trademark filings aim to protect the brand from copycats and ensure product authenticity in the regenerative medicine market.
ADIA Nutrition Inc. (OTC Pink: ADIA) ha presentato domande di registrazione del marchio presso l'USPTO per il suo nuovo prodotto 'Adia Vita' e lo slogan 'Il Platino Standard nella Terapia con Cellule Staminali.' Il nuovo prodotto a marchio privato dell'azienda, Adia Vita, presenta un contenuto verificato da terze parti di 100 milioni di cellule staminali e 3 trilioni di esosomi per unità.
Il prodotto è ora disponibile per l'acquisto tramite Adia Labs per medici e cliniche per prove e ricerche. Secondo il CEO Larry Powalisz, queste domande di registrazione del marchio mirano a proteggere il marchio da imitazioni e garantire l'autenticità del prodotto nel mercato della medicina rigenerativa.
ADIA Nutrition Inc. (OTC Pink: ADIA) ha presentado solicitudes de marca registrada ante la USPTO para su nuevo producto 'Adia Vita' y el eslogan 'El Estándar Platino en Terapia con Células Madre.' El nuevo producto de marca privada de la empresa, Adia Vita, cuenta con un contenido verificado por terceros de 100 millones de células madre y 3 billones de exosomas por unidad.
El producto ya está disponible para su compra a través de Adia Labs para médicos y clínicas para ensayos e investigaciones. Según el CEO Larry Powalisz, estas solicitudes de marca tienen como objetivo proteger la marca de imitadores y garantizar la autenticidad del producto en el mercado de la medicina regenerativa.
ADIA Nutrition Inc. (OTC Pink: ADIA)는 USPTO에 새로운 제품 'Adia Vita'와 슬로건 '줄기세포 치료의 플래티넘 기준'에 대한 상표 출원을 했습니다. 회사의 새로운 프라이빗 라벨 제대혈 줄기세포 제품인 Adia Vita는 단위당 1억 개의 줄기세포와 3조 개의 엑소좀의 제3자 검증 콘텐츠를 특징으로 합니다.
이 제품은 현재 Adia Labs를 통해 의사 및 클리닉에 시험 및 연구를 위해 구매할 수 있습니다. CEO인 Larry Powalisz에 따르면, 이러한 상표 출원은 브랜드를 모방자로부터 보호하고 재생 의학 시장에서 제품의 진정성을 보장하는 것을 목표로 하고 있습니다.
ADIA Nutrition Inc. (OTC Pink: ADIA) a déposé des demandes de marque auprès de l'USPTO pour son nouveau produit 'Adia Vita' et le slogan 'La norme Platinum en thérapie par cellules souches.' Le nouveau produit à marque privée de l'entreprise, Adia Vita, présente un contenu vérifié par des tiers de 100 millions de cellules souches et 3 trillions d'exosomes par unité.
Le produit est désormais disponible à l'achat via Adia Labs pour les médecins et les cliniques pour des essais et des recherches. Selon le PDG Larry Powalisz, ces dépôts de marque visent à protéger la marque contre les contrefaçons et à garantir l'authenticité du produit sur le marché de la médecine régénérative.
ADIA Nutrition Inc. (OTC Pink: ADIA) hat beim USPTO Markenanmeldungen für sein neues Produkt 'Adia Vita' und den Slogan 'Der Platinstandard in der Stammzelltherapie' eingereicht. Das neue Private-Label-Produkt des Unternehmens, Adia Vita, weist einen von Dritten verifizierten Inhalt von 100 Millionen Stammzellen und 3 Billionen Exosomen pro Einheit auf.
Das Produkt ist jetzt über Adia Labs für Ärzte und Kliniken für Tests und Forschungen erhältlich. Laut CEO Larry Powalisz zielen diese Markenanmeldungen darauf ab, die Marke vor Nachahmern zu schützen und die Produktauthentizität im Bereich der regenerativen Medizin sicherzustellen.
- Launch of new stem cell product with verified high cell count
- Product already available for medical trials and research
- Strategic brand protection through trademark filings
- distribution channel (only to doctors/clinics)
- Pending trademark approvals - not yet secured
- Early stage product without proven market acceptance
Winter Park, Florida--(Newsfile Corp. - March 5, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a frontrunner in health and wellness innovation, is fortifying its brand legacy by filing trademark applications with the U.S. Patent and Trademark Office (USPTO) for its new product, "Adia Vita," and its bold slogan, "The Platinum Standard in Stem Cell Therapy," both now pending approval. The purpose of these trademarks is to protect ADIA Nutrition's brand from copycats who use inferior products, ensuring that its premier stem cell offerings remain synonymous with authenticity and excellence in the fast-growing field of regenerative medicine.
Adia Vita Unveiled - Meet Adia Vita, Adia Nutrition's groundbreaking entry into stem cell therapy. This private-label umbilical cord stem cell product sets a new bar with a guaranteed, third-party-verified 100 million stem cells and 3 trillion exosomes per unit, designed for those pursuing cutting-edge health solutions. (Now available for purchase through Adia Labs to doctors and clinics for trials and research.)
Cannot view this image? Visit:
https://images.newsfilecorp.com/files/10520/243145_2.jpg
The Platinum Standard - The Platinum Standard - The slogan "The Platinum Standard in Stem Cell Therapy," currently pending trademark approval with the USPTO, reflects Adia Nutrition's commitment to setting a new benchmark in the industry. "The gold standard had its day—noble, sure, but a bit past its prime," said Larry Powalisz, CEO of Adia Nutrition. "Platinum represents the future—refined, resilient, and poised to lead stem cell therapy into its next era."
Cannot view this image? Visit:
https://images.newsfilecorp.com/files/10520/243145_1.jpg
"Filing for these trademarks is about more than just legal protection—it's about promising our customers the real deal, every time," Powalisz added. "With 'Adia Vita' and 'The Platinum Standard,' we're locking in our vision for innovation and trust."
These trademark efforts highlight Adia Nutrition's strategy to stand out in a crowded market, giving patients and providers confidence in the authenticity and superiority of its offerings.
Adia Nutrition invites media inquiries and looks forward to sharing how these bold steps will continue to push the boundaries of stem cell therapy, opening doors to transformative health advancements.
For inquiries, questions, or further information, you can contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243145
FAQ
What are the key features of ADIA's new stem cell product Adia Vita?
Who can currently purchase ADIA's Adia Vita stem cell product?
What trademarks has ADIA Nutrition filed with the USPTO in March 2025?
What is the purpose of ADIA's recent trademark filings?
